CORTCorcept Therapeutics Inc
$114.15
$21.20
(22.81%)
Pre-Market
Reported EarningsJul 29
Mkt Cap$10.11B
Vol7,713.00
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the...
Business Wire
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Zacks
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call...
Business Wire
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law...
PR Newswire
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
Zacks
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushings Syndrome
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted...
Business Wire
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Zacks
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of...
Business Wire
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
<
1
2
>
Advertisement|Remove ads.
LMND2
6
NBIS12
18
SOFI7
10Advertisement|Remove ads.